$CTMX News
Last published 6d ago
- 6d agoCTMXCytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateGlobeNewswire- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data...
- 6d agoCTMXCytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateGlobeNewswire- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in
- 6d agoCTMXCytomX Therapeutics, Inc. - CYTOMX Q3 2026 EARNINGS RELEASE_DRAFT_POST_AC_FOR APPROVALEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoCTMXCytomX Therapeutics Third Quarter 2026 Financial Results - CYTOMX THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. Thank you for standing by. Welcome to CitimX's Therapeutics Third Quarter 2026 Financial Results Call. Please be advised that today's call is being recorded. I would now like to hand the call ov
- 1w agoCTMXCytomX Therapeutics to Present at Upcoming November Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will
- 2w agoCTMXCytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third
- 1mo agoCTMXCytomX Therapeutics Inc - 1774756 - CYTOMX THERAPEUTICS INCEarnings Call TranscriptsGreat afternoon, everybody. We're pleased to have Cytomics with us for the next fireside. Chris, I'm going to turn it over to you to maybe make some opening comments, and then we can jump into it. Yeah. Hi, everyone, and
- 1mo agoCTMXMorgan Stanley 24th Annual Global Healthcare Conference - CYTOMX THERAPEUTICS INCEarnings Call TranscriptsGreat afternoon, everybody. We're pleased to have Cytomics with us for the next fireside. Chris, I'm going to turn it over to you to maybe make some opening comments, and then we can jump into it. Yeah. Hi, everyone, and
- 1mo agoCTMXMorgan Stanley 24th Annual Global Healthcare Conference - CYTOMX THERAPEUTICS INCEarnings Call TranscriptsGreat afternoon, everybody. We're pleased to have Cytomics with us for the next fireside. Chris, I'm going to turn it over to you to maybe make some opening comments, and then we can jump into it. Yeah. Hi, everyone, and
- 2mo agoCTMXCytomX Therapeutics to Present at Upcoming September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will
- 2mo agoCTMXCytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)GlobeNewswire- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN
- 3mo agoCTMXCYTOMX THERAPEUTICS SECOND QUARTER 2026 FINANCIAL RESULTS - CYTOMX THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. Thank you for standing by. Welcome to the Cytomics Therapeutics Second Quarter 2026 Financial Results Call. Please be advised that today's call is being recorded. I would now like to hand the ca
- 3mo agoCTMXCytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business UpdateGlobeNewswireVarsetatug masetecan ("Varseta-M") Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1
- 3mo agoCTMXCytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Alejandra
- 3mo agoCTMXCytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report second
- 3mo agoCTMXCytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles
- 4mo agoCTMXANNUAL MEETING OF STOCKHOLDERS - CYTOMX THERAPEUTICS, INC.Earnings Call TranscriptsWelcome to the 2026 Annual Meeting of Cytomics Therapeutics, Inc. Good afternoon, ladies and gentlemen. It's my pleasure to welcome you to the virtual 2026 Annual Meeting for Stockholders of CYtomics Th therapeutics. I'm
- 5mo agoCTMXCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of CancerGlobeNewswire- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $37
- 5mo agoCTMXCytomX Therapeutics to Present at Upcoming June Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will
- 5mo agoCTMXCytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory AffairsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata
- 6mo agoCTMXCytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business UpdateGlobeNewswire- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose
- 6mo agoCTMXCytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first
- 8mo agoCTMXCytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an
- 8mo agoCTMXCytomX Therapeutics Announces 2025 Financial Results and Provides Business UpdateGlobeNewswire- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with
- 8mo agoCTMXCytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal CancerGlobeNewswire- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea
- 8mo agoCTMXCytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year
- 9mo agoCTMXCytomX Therapeutics to Present at Upcoming February ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will
- 9mo agoCRDFCTMXCardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical DevelopmentGlobeNewswireSAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 10mo agoCTMXCytomX Therapeutics Announces Business Update and Company Milestones for 2026GlobeNewswire- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1
- 11mo agoCTMXCytomX Therapeutics to Present at Upcoming December Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will
- 12mo agoCTMXCytomX Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil.,
- 1y agoCTMXCytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of
- 1y agoCTMXCytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswire- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801's mechanism of action and the
- 1y agoCTMXCytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third
- 1y agoCTMXCytomX Therapeutics Appoints Rachael Lester as Chief Business OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael
- 1y agoCTMXCytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoCTMXCytomX Therapeutics to Present at Upcoming September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will
- 1y agoCTMXCytomX Therapeutics Provides Update on CX-2051 Phase 1 StudyGlobeNewswire- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients
- 1y agoCTMXCytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCTMXCytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track
- 1y agoCTMXCytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will
- 1y agoCLDIVRTXIBRXCRSP+1Breaking Through: Systemic Genetic Medicines for Hard-to-Treat CancersPR NewswireEach year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is...
- 1y agoCTMXCytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil.,
- 1y agoCTMXCytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic MelanomaGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been
- 1y agoCTMXCytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an
- 1y agoCTMXCytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose
- 1y agoCTMXCytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)GlobeNewswire- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper
- 1y agoCTMXCytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first
- 1y agoCTMXCytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced new preclinical data in
- 1y agoCTMXCytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateGlobeNewswire- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY®